Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus UTICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus UTICORT.
ARAZLO vs UTICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Uticort (betamethasone) is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Topical: Apply a thin film to affected area twice daily. Maximum 50 g per week. For short-term use only (≤2 weeks).
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life: 2-4 hours in healthy adults; prolonged to 6-12 hours in hepatic impairment.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% via enterohepatic circulation.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid